Journal
THROMBOSIS AND HAEMOSTASIS
Volume 109, Issue 1, Pages 24-33Publisher
GEORG THIEME VERLAG KG
DOI: 10.1160/TH12-05-0302
Keywords
F9; haemophilia B; mutation; FIX inhibitors; CSGE
Categories
Funding
- Rene Baron Foundation
- Alberto J. Roemmers Foundation
- Florencio Fiorini Foundation
- Novo Nordisk Argentina
- Academia Nacional de Medicina de Buenos Aires
- National Research Council (CONICET)
- National Agency for Science and Technology Promotion (ANPCyT)
- Word Federation of Hemophilia
Ask authors/readers for more resources
In haemophilia B (HB) (factor IX [FIX] deficiency), F9 genotype largely determines clinical phenotype. Aimed to characterise Argentinian families with HB, this study presents F9 genotype frequencies and their specific FIX inhibitor risk and 10 novel F9 mutations. Ninety-one DNA samples from HB patients and relatives were subjected to a new; scheme: a primary screen for large deletions, a secondary screen for point mutations using conformation sensitive gel electrophoresis, DNA-sequencing and bioinformatic analysis. Our unbiased HB population (N=52) (77% with severe, 11.5% moderate and 11.5% mild HB) showed 32 missense (61.5%), including three novel mutations predicting specific structural/functional defects in silico, seven nonsense (13.5%) (one novel), five large deletions, four splice including three novel mutations affecting predicted splicing scores, three indels (two novel) and one Leiden mutation. Our comprehensive HB population included five patients with long-lasting FIX inhibitors: three nonsense (p.E35(star) (novel), p.R75(star), p.W240(star)) and two entire-F9 deletions. Another patient with an indel (p.A26Rfsp(star)14) developed transient inhibitors. A case-control analysis, based on our global prevalence of 3.05% for developing inhibitors in HB revealed that missense mutations were associated with a low risk odds ratio (OR) of 0.05 and a prevalence of 0.39%, whereas nonsense and entire-F9 deletions had significantly higher risks (OR 11.0 and 32.7) and prevalence (14.3%, and 44.5%, respectively). Our cost-effective practical approach enabled identification of the causative mutation in all 55 Argentine families with HB, analysis of the molecular pathology of novel F9 defects and determination of mutation-associated FIX inhibitor risks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available